Every state Medicaid program in the United States now has paperwork in front of the federal government on the same drug-pricing arrangement. The Centers for Medicare & Medicaid Services said on September 18 that all 50 states, along with the District of Columbia and Puerto Rico, have applied to a model built to buy brand-name Medicaid drugs at prices set by what wealthy foreign countries pay. Forty of those states and Puerto Rico have already signed participation agreements. The rest are working against a deadline at the end of this month.
Fifty-two applications, forty-one signatures, and a September 30 deadline
The gap between applying and signing is the substance of the announcement, and CMS is the agency that keeps both counts. In its announcement of model participants, the agency reported that every state Medicaid program plus the District of Columbia and Puerto Rico had applied to the GENEROUS model, that 40 states and Puerto Rico had signed agreements to participate, and that the states still unsigned have until September 30, 2026 to complete them.
That timetable was set months ago. A CMS news alert issued on April 29, 2026 moved the state application deadline from July 31 to September 10, 2026, and pushed the date for finalizing state participation agreements from August 31 to September 30, 2026. The same alert traces the model back to its announcement in November 2025.
Nothing in the agency’s record shows a state standing outside the arrangement. No state Medicaid agency is missing from the applicant list, and none is recorded as having pulled back. What separates the signed from the unsigned is the calendar and the state plan paperwork underneath each signature, not a decision to opt out.
Free download: What to ask the plan, the prescriber and the pharmacy, when to request an exception, and which records to keep. Download the free prescription coverage checklist.
Supplemental rebates, invoiced quarterly, measured against foreign net prices
The mechanism is a most-favored-nation benchmark, and it works through rebates rather than through a new price tag on the shelf. CMS explains the machinery on the GENEROUS model page: participating manufacturers enter negotiated agreements with CMS covering their portfolio of covered outpatient drugs, with pricing calculated from select international pricing data. Participating states then invoice those manufacturers quarterly for supplemental rebates that pull the net Medicaid price down to the foreign level. CMS monitors whether the payments are accurate and takes a share of the rebates back through a reduction in the federal share of Medicaid payments.
What falls inside the model is narrower than the word “drugs” suggests. The scope covers single-source and innovator multiple-source covered outpatient drugs belonging to manufacturers that volunteer — brand-name medicines without generic competition. CMS has named AstraZeneca, Pfizer and EMD Serono as companies whose separate agreements with the administration commit them to the model once certain terms are finalized. The yardstick in the agency’s own documents is the price paid in select other developed countries, the group that includes the European markets where the same brand-name medicines have long sold for a fraction of American prices. The April alert describes the target as prices “aligned with those paid in select other countries.”
Why the $64.3 billion estimate lands on state budgets, not pharmacy counters
CMS put the projected taxpayer saving at $64.3 billion over ten years. That number is a projection rather than a booked result, and it carries an oddity worth noticing: the model launched in January 2026 and runs for five years, so the savings horizon is twice the length of the program that produces it. Anyone reading the figure as money already in hand is reading it wrong.
The agency is also direct about who benefits. Among the model’s stated aims is lowering what federal and state governments spend on prescription drugs, providing savings to state Medicaid programs and federal taxpayers over time. Relief at the counter is framed as a possibility, not a promise — CMS writes that the model may improve access to the included drugs in participating states. The problem it is built against is a budget problem: net Medicaid spending on prescription drugs topped $60 billion in 2024, a $10 billion increase over 2022.
What a signed agreement still leaves to each state
A signature does not reprice a state’s entire formulary. The model is voluntary for state Medicaid agencies, and CMS confirms that each participating state decides for which covered outpatient drugs — if any — it wants the international price from a given participating manufacturer. A state weighing that choice can look at whether a drug is already cheaper after existing manufacturer rebates and at the supplemental rebate agreements it has signed elsewhere. The state application sits on top of real machinery: participation requires membership in the Medicaid Drug Rebate Program, CMS authorization to enter the necessary supplemental rebate agreements through the state plan amendment process, and operational and systems work including alignment with Medicaid managed care organizations.
That is where the two federal descriptions of September 18 part company. A White House fact sheet published the same day presents the arrangement as settled across all 50 state Medicaid programs. CMS, the agency that administers the model and holds the signatures, publishes a more exact record for that date: 52 applications, 41 signed agreements counting Puerto Rico, and an open deadline for the remainder. Where the two accounts differ, the administering agency’s count governs. And the agency’s own model page, last modified on July 1, 2026, still lists the GENEROUS stage as announced and its participant count as not applicable — a page CMS will need to refresh before the record online matches the record in its press releases.
Where the Medicaid Rebate Deal Stops and Medicare Rules Begin
GENEROUS reaches Medicaid pharmacy spending and stops there. A household covered by Medicare sits under a different statute, a different appeal route and a different set of state programs, and the protections that matter most there tend to be the ones nobody prints side by side — the annual spending limit in one place, the appeal window in another, the state help programs in a third.
The Medicare Cost & Coverage Protection Kit is a 10-page kit that lays out the new Part D out-of-pocket cap, the prior-authorization appeal steps, and 51 state Medicare cost-help packs.
See the prior-authorization appeal steps in The Medicare Cost & Coverage Protection Kit.
AI-assisted research and drafting; reviewed by an editor.
